Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation
Open Access
- 20 June 2006
- journal article
- clinical trial
- Published by Frontiers Media SA in Transplant International
- Vol. 19 (8) , 629-635
Abstract
Thymoglobulin is used effectively as an induction agent in kidney transplantation, but the optimal dose is not well established. We evaluated the degree and durability of T‐cell clearances with two different thymoglobulin regimens in adult kidney transplant recipients (KTR). Seven KTR received a 3‐day thymoglobulin‐based induction of 1.0 mg/kg/day while nine received 1.5 mg/kg/day, in addition to maintenance immunosuppression. Lymphocyte subsets were monitored for 6 months. Renal function, infections and malignancies were monitored for 24 months. T‐cell subsets were significantly lower by day 30 with the thymoglobulin 1.5 mg/kg/day regimen when compared with the 1.0 mg/kg/day regimen; this trend was sustained at 6‐month (CD3+: 438 ± 254 vs. 1001 ± 532 cells/mm3, P = 0.016). Renal function between the two groups was not significantly different at 6‐ and 24‐months post‐transplant. One case of BK Virus viremia in the 1.5 mg/kg/day thymoglobulin group was detected. No acute rejection episodes, cytomegalovirus infections, or malignancies were noted in either group. Thymoglobulin induction was efficacious in both groups, but with a significantly sustained T‐cell clearance in the 1.5 mg/kg/day regimen. A more profound T‐cell clearance within the first 6 months postinduction therapy may translate into a decreased risk of immunological injury and improved long‐term outcome after kidney transplantation.Keywords
This publication has 22 references indexed in Scilit:
- A Prospective Randomized Trial of Steroid-Free Maintenance Regimens in Kidney Transplant Recipients—An Interim AnalysisAmerican Journal of Transplantation, 2005
- Immunosuppression: evolution in practice and trends, 1993–2003American Journal of Transplantation, 2005
- ATG induction therapy: long-term effects on Th1 but not on Th2 responsesTransplant International, 2005
- Selective intra-graft apoptosis and down-regulation of lymphocyte bcl-2, iNOs and CD95L expression in kidney-pancreas transplanted patients after anti-Thymoglobulin inductionTransplant International, 2004
- Polyclonal anti-thymocyte globulins influence apoptosis in reperfused tissues after ischaemia in a non-human primate modelTransplant International, 2004
- A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1Transplantation, 2003
- Prospective Study of Polyomavirus Type BK Replication and Nephropathy in Renal-Transplant RecipientsNew England Journal of Medicine, 2002
- LOW DOSE ANTITHYMOCYTE GLOBULINS IN RENAL TRANSPLANTATIONTransplantation, 2000
- COMPARATIVE POLYCLONAL ANTITHYMOCYTE GLOBULIN AND ANTILYMPHOCYTE/ANTILYMPHOBLAST GLOBULIN ANTI-CD ANTIGEN ANALYSIS BY FLOW CYTOMETRYTransplantation, 1995
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976